Infections caused by non–carbapenemase-producing carbapenem-resistant Enterobacteriaceae present challenges in the treatment paradigm. Given the limited clinical data, the preferred therapeutic approach remains unknown.
BEJOY PAUL MANIARA, PHARMD, BCPS, BCIDP
Advertisement
Articles by BEJOY PAUL MANIARA, PHARMD, BCPS, BCIDP
Advertisement
Latest Updated Articles
- The Search Continues for How to Best Treat Non—Carbapenemase-Producing CRE Infections
Published: April 8th 2020 | Updated:
Advertisement
Advertisement
Trending on Contagion Live
1
Moderna Discontinues Development of Vaccine for Congenital CMV After Not Meeting Primary Efficacy Endpoint
2
Dynavax Presents Data for Shingles Vaccine, Launches Head-to-Head Study Against Shingrix
3
Meet SIDP’s President Elect: Lisa Dumkow, PharmD, FIDP, BCIDP
4
Introducing Cefiderocol Earlier in Difficult-to-Treat-Infections
5
